Evidence map›Paper›PMID 34781955›Full record

Trial reportBMC oral health2021

Efficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial.

Boróka Klára Csifó-Nagy, Eleonóra Sólyom, Vera Lili Bognár, Annamária Nevelits, Ferenc Dőri

2 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC oral health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 18 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04404374 nacompletednot on this map

Efficacy of a New-generation Platelet-rich Fibrin vs. Enamel Matrix Derivatives in the Treatment of Periodontal Intrabony Defects : a Randomized Clinical Trial

TypeinterventionalSponsorSemmelweis UniversityRan2018 to 2020Enrolled30ConditionsPeriodontal DiseasesArmsA-PRF/EMD
NCT05360511 early_phase1completednot on this mapstarted 2022, after this paper: background citation

Erythropoietin Gel as an Adjunct to Xenograft in the Surgical Management of Intrabony Periodontal Defects. A Randomized Controlled Clinical Study

TypeinterventionalSponsorAin Shams UniversityRan2022 to 2023Enrolled26ConditionsPeriodontal Bone LossArmsparticulate xenograft + erythropoietin gel., particulate xenograft
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Boróka Klára Csifó-NagyDepartment of Periodontology, Faculty of Dentistry, Semmelweis University, Szentkirályi u. 47., Budapest, 1088, Hungary. drcsifo@gmail.com.ORCID 0000-0001-9454-2916
Eleonóra SólyomDepartment of Periodontology, Faculty of Dentistry, Semmelweis University, Szentkirályi u. 47., Budapest, 1088, Hungary.
Vera Lili BognárDepartment of Periodontology, Faculty of Dentistry, Semmelweis University, Szentkirályi u. 47., Budapest, 1088, Hungary.
Annamária NevelitsDepartment of Periodontology, Faculty of Dentistry, Semmelweis University, Szentkirályi u. 47., Budapest, 1088, Hungary.
Ferenc DőriDepartment of Periodontology, Faculty of Dentistry, Semmelweis University, Szentkirályi u. 47., Budapest, 1088, Hungary.
Semmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of the study was to clinically evaluate the healing of intrabony defects after treatment with a new generation of platelet-rich fibrin (A-PRF+) respect to enamel matrix derivative (EMD).

methodsThirty (30) intrabony defects of 18 patients (9 males, 9 females) were randomly treated with A-PRF+ (test, n = 15) or EMD (control, n = 15). The following clinical parameters were recorded at baseline and 6 months after surgery: pocket depth (PD), gingival recession (GR) and clinical attachment level (CAL). After debridement the intrabony defects were filled with A-PRF+ in the test group, respectively with EMD in the control group, and fixed with sutures to ensure wound closure and stability.

resultsBoth treatment methods resulted in statistically significant PD reductions, respectively CAL gains six months post-operatively. No statistically significant differences were found between the two groups as the mean CAL gain was 2.33 ± 1.58 mm in the A-PRF+ group, respectively 2.60 ± 1.18 mm in the EMD group (p < 0.001).

conclusionWithin the limits of this study the new-generation platelet-rich fibrin seems to be as clinically effective as EMD during surgical treatment of intrabony defects. Treatment with A-PRF+ or EMD resulted in reliable clinical outcomes. The use of A-PRF+ as a human autologous product can give a positive impact on periodontal healing. Clinical Relevance A-PRF+ may be suitable for the treatment of intrabony periodontal defects. Trial registration number (TRN) NCT04404374 (ClinicalTrials.gov ID).

Indexed as

Alveolar Bone LossDental Enamel ProteinsGingival RecessionPlatelet-Rich FibrinFemaleGuided Tissue Regeneration, PeriodontalHumansMalePeriodontal Attachment LossTreatment OutcomeDental Enamel ProteinsAdvanced platelet-rich fibrinEnamel matrix derivativeIntrabony defectsPeriodontal healing

Identifiers

PMID34781955
PMCPMC8591936
OpenAlexW3164122788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.